Professional or Occupational Group
RFK Jr. Fires Top HHS Leadership in Major Department Shakeup
RFK Jr.; HHS; leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; health policy; White House liaison
RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief
RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy
RFK Jr. Fires Top Deputies, Reshuffles Leadership at HHS
Robert F. Kennedy Jr.; Health and Human Services; leadership reshuffle; chief of staff; personnel changes; Matt Buckham; Trump loyalists; Heather Flick Melanson; Hannah Anderson
RFK Jr. Reshuffles Top HHS Leadership, Names New Acting Chief of Staff
RFK Jr.; HHS; leadership shakeup; chief of staff; personnel changes; Matt Buckham; Heather Flick Melanson; Hannah Anderson; health policy; Department of Health and Human Services
RFK Jr. Fires Two Top Aides in Major HHS Leadership Reshuffle
Robert F. Kennedy Jr.; HHS; chief of staff; leadership shakeup; personnel change; Make America Healthy Again
Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical
Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership
RFK Jr. Ends CDC Covid Vaccine Recommendations for Healthy Children and Pregnant Women
RFK Jr.; COVID-19 vaccine; recommendations; children; pregnant women; CDC; HHS Secretary; public health policy
About 5% of CBER and CDER Left After FDA Staff Cuts, Analysis Finds
FDA layoffs; CBER; CDER; drug review; biologics; staff cuts; Trump administration; drug approval process
Eikon Therapeutics Implements Second Major Staff Reduction in Under Two Years
Eikon Therapeutics; layoffs; biotech; staff cuts; funding cuts; research instrument development; workforce reduction; Roger Perlmutter
Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus
Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101